Advertisement
U.S. markets open in 5 hours 45 minutes

KalVista Pharmaceuticals, Inc. (KALV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
11.99+0.06 (+0.50%)
At close: 04:00PM EDT
11.99 0.00 (0.00%)
After hours: 04:28PM EDT

KalVista Pharmaceuticals, Inc.

55 Cambridge Parkway
Suite 901 East
Cambridge, MA 02142
United States
857 999 0075
https://www.kalvista.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees118

Key Executives

NameTitlePayExercisedYear Born
Mr. Benjamin L. PalleikoCEO & Director707.1kN/A1966
Dr. Christopher M. Yea Ph.D.Chief Development Officer640.23kN/A1964
Dr. Edward P. Feener Ph.D.Chief Scientific Officer506kN/A1960
Mr. Ryan BakerHead of Investor RelationsN/AN/AN/A
Mr. Brian Krex J.D.General CounselN/AN/A1968
Jarrod AldomVice President of Corporate CommunicationsN/AN/AN/A
Ms. Rachel M. MortenSenior Vice President of Regulatory Affairs & QAN/AN/AN/A
Dr. Michael D. Smith Pharm.D.Senior Vice President of DevelopmentN/AN/A1980
Dr. Paul K. Audhya M.B.A., M.D.Chief Medical OfficerN/AN/A1973
Ms. Nicole SweenyChief Commercial OfficerN/AN/A1976
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Corporate Governance

KalVista Pharmaceuticals, Inc.’s ISS Governance QualityScore as of March 1, 2024 is 7. The pillar scores are Audit: 6; Board: 7; Shareholder Rights: 5; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.